On October 15, 2025, Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for common dermatologic conditions, announced the completion of an oversubscribed $150 million Series C financing. SR One led the funding round, with participation from new investors Viking Global Investors, Marshall Wace, Invus, funds managed by abrdn Inc., Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, and current investors including Longitude Capital, Suvretta Capital Management, Surveyor Capital, and other undisclosed investors. Wilson Sonsini Goodrich & Rosati advised lead investor SR One on the transaction.

Proceeds from the financing are intended to advance and complete Veradermics’ ongoing Phase 3 trials and, if the clinical data are supportive, a subsequent New Drug Application submission to the U.S. Food and Drug Administration for VDPHL01.

The Wilson Sonsini team that advised SR One on the transaction includes Dan Koeppen, Kassandra Castillo, James Keegan, Michael Hostetler, and Uale Taotafa.

For more information, please see Veradermics' news release. Additional coverage can be found on Fierce Pharma.